Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-26 · accession 0001079973-25-000525 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-03-28 | 2025-03-26 | STLN | Pacala Mark L | Dir | P - Purchase | $1.04 | +90.6K | 225.0K | +67% | +$94.2K |
| DI | 2025-03-28 | 2025-03-26 | STLN | Pacala Mark L | Dir | P - Purchase | $0.13 | +42.3K | 42.3K | New | +$5,497 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-26 | P | A | 90,562 | $1.04 | 224,971 | I By LLC | — | — | (F2) Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. (F3) Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein. |
| 2 | Derivative | Common Warrant | 2025-03-26 | P | A | 42,281 | $0.13 | 42,281 | I By LLC | $1.20 · 2025-03-26 to 2030-03-26 | 42,281 Common Stock | (F1) Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit"). (F2) Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250. (F3) Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein. (F4) The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended. |